ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Overall Hypothesis: Endothelin-1 (ET1) and associated dysregulation of key metabolic pathways decrease pre-operative pulmonary blood vessel development and increase post-operative pulmonary blood vessel resistance leading to decreased pulmonary blood flow in patients undergoing SCPA.
For enrolled patients, collected data will include:
- 3 mL blood sample (x2) at pre-SCPA catheterization.
- 3 mL blood samples at 2, 24, and 48 hours post-operative.
- Urine sample pre-operatively and post-operatively
- Collection of otherwise-discarded operative tissue sample from the pulmonary artery.
- Collection of clinical data, demographic data, and results of routine, post-operative hemodynamic monitoring.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Benjamin Frank, MD
- Phone Number: 720 777 1954
- Email: Benjamin.Frank@childrenscolorado.org
Study Contact Backup
- Name: Jesse Davidson, MD
- Email: Jesse.Davidson@childrenscolorado.org
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Congenital heart disease patients undergoing catheterization for pre-SPCA evaluation or undergoing SCPA without plans for cardiac catheterization (utilizing data from a previously performed clinical catheterization).
- All patients will have age from 31 days to 2 years.
Exclusion Criteria:
- Patients who will remain post-op with a pulsatile source of pulmonary blood flow in addition to the cavo-pulmonary anastomosis (so called "1.5 ventricle" repair) will be excluded.
- Due to limitations in acceptable sample blood volumes for research, patients with weight <4kg will be excluded.
- Patients will not be excluded on the basis of gender, ethnicity, genetic diagnosis, gestational age at birth, non-cardiac comorbidity, or pre-operative medication regimen.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Study Patients
Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
|
Blood samples will be collected at specified time points and research assays will be performed.
|
|
Control Patients
Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
|
Blood samples will be collected at specified time points and research assays will be performed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference in ET1 concentration between controls, study patients at pre-SCPA catheterization, and study patients in the post-operative period.
Time Frame: 48 hours post-operatively
|
48 hours post-operatively
|
|
Difference in metabolomics profile between controls, study patients at pre-SCPA catheterization, and study patients in the post-operative period.
Time Frame: 48 hours post-operatively
|
48 hours post-operatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Association between ET1 concentration at pre-SCPA catheterization in study patients and clinical metrics of pre-operative pulmonary adequacy.
Time Frame: 48 hours post-operatively
|
48 hours post-operatively
|
|
Association between metabolomics profile in study patients and clinical metrics of pre-operative pulmonary adequacy.
Time Frame: 48 hours post-operatively
|
48 hours post-operatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Benjamin Frank, MD, University of Colorado, Denver
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17-0832
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Single-ventricle
-
NCT01149603WithdrawnSingle-ventricle | Failing Fontan Physiology | Failing Fontan | Single-ventricle Fontan | Single-ventricle Physiology
-
NCT03575572TerminatedHeart Diseases | Single-ventricle
-
NCT05063903CompletedSingle-ventricle | Fontan Procedure
-
NCT00166218TerminatedAmbulatory Children With Single Ventricle
-
NCT06538571RecruitingSingle-ventricle
-
NCT04017494Not yet recruiting
-
NCT01917084CompletedSingle Ventricle Physiology
-
NCT05918211RecruitingSingle Ventricle Heart Disease
-
NCT02741115CompletedSingle Ventricle Heart Disease
Clinical Trials on Research Blood Sampling
-
NCT07356752Active, not recruitingLung Transplantation | Graft Dysfunction | Chronic Rejection of Lung Transplant | Chronic Lung Allograft Dysfunction (CLAD)
-
NCT03170297Completed
-
NCT04025541RecruitingGlioma | Sarcoma | Cancer | Breast Cancer | Colon Cancer | Lung Cancers
-
NCT02711332Completed
-
NCT04001114CompletedSchizophrenia | Tobacco Dependence
-
NCT04907773Completed
-
NCT05854368RecruitingGastric Cancer | Gastric Precancerous Condition | Gastric Lesion
-
NCT03788772CompletedSepsis | Acute Circulatory Failure
-
NCT06891508Active, not recruiting
-
NCT03857997CompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)